paywalled: Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study

WIKI: Lipid metabolism refers to the processes that involve the intercourse and degradation of lipids.
The types of lipids involved include:

• Bile salts
• Cholesterols
• Eicosanoids
• Glycolipids
• Ketone bodies
• Fatty acids - see also fatty acid metabolism
• Phospholipids
• Sphingolipids
• Steroid - see also steroidogenesis
• Triacylglycerols (fats) - see also lipolysis and lipogenesis

                                                ~~~~~~~~~~~~~~~~~
Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study

Background: 

Obesity is a risk factor for breast (BCa) and ovarian cancer (OCa); the mechanisms of action are not completely understood. Perturbed lipid metabolism often accompanies obesity; we therefore ascertained the associations between lipid components and BCa and OCa risk in a prospective cohort study. 

Methods: 

234,494 women with baseline measurements of triglycerides (TG) and total cholesterol(TC) and glucose were selected from the AMORIS database. 27,394 had measurements of HDL,LDL, apolipoprotein (Apo) B and A-I. Associations between quartiles and dichotomized values of lipid components and BCa and OCa risk were analysed using Cox proportional hazard models.

Results: 

We identified 6,105 women diagnosed with BCa and 808 women diagnosed with OCa. A weak trend was observed between TG and BCa (HR: 1.01 (CI95% 0.94-1.09), 0.93 (0.86-1.00) 0.91 (0.84-0.99) 2nd 3rd and 4th quartiles; P = 0.01). No other associations between lipid components and risk of BCa or OCa showed statistical significance. 

Conclusions: 

A weak protective association was found between levels of TG and risk of BCa. 

Impact: An analysis including information on tumour characteristics of OCa and BCa may provide more insight in possible links between lipid metabolism and the risk of these cancers.

Safety Alerts Cite Cholesterol Drugs’ Side Effects - NYTimes.com

Safety Alerts Cite Cholesterol Drugs’ Side Effects - NYTimes.com

PLoS ONE: Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy

Blogger's Note: Table S1 does not specifically show gyn/ovarian cancers unless they have been reported in 'other' or 'unspecified'; a search of the document for 'gyn'/'ovarian'/'ovary' did not provide a result

Background

Statin therapy reduces the risk of occlusive vascular events, but uncertainty remains about potential effects on cancer. We sought to provide a detailed assessment of any effects on cancer of lowering LDL cholesterol (LDL-C) with a statin using individual patient records from 175,000 patients in 27 large-scale statin trials.


Table S1.
Number of patients with a report of cancer (number of cancer deaths), by site and trial.
(PDF)

Conclusion

"........ The present report now demonstrates clearly that such reductions in LDL cholesterol do not increase the rate of cancer or cancer death, overall or at any particular site, during a treatment period of about 5 years (and more prolonged follow-up in some of the trials does not indicate any later excess) even among older individuals or those who have their cholesterol levels reduced to very low levels. These findings provide considerable reassurance about the safety of using more intensive statin regimens to lower LDL cholesterol levels substantially in patients who remain at high risk of major vascular events."

Soy won't reduce cholesterol after menopause: MedlinePlus